Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | ASPH | Q12797 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10590680 | 0.82 | FAAH (0.50) | FAAHCES1KMT2AAGBL2MAPT | |
| SCHEMBL11930611 | 0.81 | FAAH (0.43) | FAAHCES1LMNA | |
| SCHEMBL11937006 | 0.79 | FAAH (0.52) | FAAHCES1AGBL2 | |
| SCHEMBL10121134 | 0.72 | — | — | |
| SCHEMBL14959509 | 0.68 | MAPT (0.41) | FAAHKMT2AALDH1A1NPSR1MAPT | |
| SCHEMBL5985190 | 0.67 | PDK2 (0.34) | FAAHCES1NPSR1LMNA | |
| SCHEMBL1706336 | 0.65 | POLB (0.37) | FAAHAGBL2RAB9A | |
| SCHEMBL5237928 | 0.65 | MEN1 (0.44) | FAAHCES1KMT2AALDH1A1MEN1 | |
| SCHEMBL13561287 | 0.64 | ACHE (0.38) | — | |
| SCHEMBL14701723 | 0.64 | TUBB4A (0.56) | FAAHCES1KMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| US-8445527-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, HAVCR2, CPT1A | FAAH 1183/4885CES1 113/4885KMT2A 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.